Skip to main content
. Author manuscript; available in PMC: 2014 Jun 19.
Published in final edited form as: J Pain. 2011 Nov 23;13(2):103–111. doi: 10.1016/j.jpain.2011.09.006

Table 3.

Significant Parameter Estimates for Policy Change Effects on Multiple Provider Episodes

Medication Model Type ß SE t-ratio Significance
SA Fentanyl ARIMA(1,0,0) 349.282 40.450 8.635 .001
LA Fentanyl ARIMA(1,0,0) 3076.314 394.381 7.800 .001
SA Hydromorphone ARIMA(1,0,0) 1301.383 313.120 4.156 .001
Meperidine ARIMA(1,0,0) 126.728 11.390 11.126 .001
Methadone ARIMA(1,0,0) 1718.412 338.130 5.082 .001
SA Morphine ARIMA(1,0,0) 627.492 62.672 10.012 .001
LA Morphine ARIMA(1,0,0) 3131.985 276.599 11.323 .001
SA Oxycodone ARIMA(1,0,0) 4580.153 1324.397 3.458 .001
LA Oxycodone ARIMA(1,0,0) 3457.444 558.850 6.187 .001

Abbreviations: SA, short-acting; LA, long-acting.